Audentes Therapeutics (BOLD) Misses Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St futures ease as Big Tech earnings rekindle AI spending worries, oil jumps
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Dollar hits fresh 40-year high versus yen, edges higher against euro
Audentes Therapeutics (BOLD) PT Raised to $32 at Evercore ISI
August 7, 2018 3:01 PM EDTEvercore ISI raised its price target on Audentes Therapeutics (NASDAQ: BOLD) to $32.00 (from $30.00) while maintaining a In Line rating.
... MoreAudentes Therapeutics (BOLD) Announces Update on ASPIRO Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy
August 7, 2018 6:23 AM EDTAudentes Therapeutics, Inc. (NASDQ: BOLD) today reported its financial results for the second quarter ended June 30, 2018 and provided an update on ASPIRO, the phase 1/2 clinical trial of AT132 in patients with X-Linked Myotubular Myopathy (XLMTM), including muscle biopsy results from the first three patients treated in the study and the week 24 efficacy analysis for Patient 3.
"We're very pleased with continued clinical progress in ASPIRO, and in particular the results of the muscle biopsy data from the first three ASPIRO patients, which show unprecedented levels of tissue transduction and protein expression from a systemically... More
